Special Issue "Antifungal Drug Development"

A special issue of Pathogens (ISSN 2076-0817).

Deadline for manuscript submissions: closed (31 January 2020).

Special Issue Editor

Prof. Ying-Lien Chen
Website
Guest Editor
Department of Plant Pathology and Microbiology, National Taiwan University, 10617 Taipei, Taiwan
Interests: antifungal drug development; human fungal pathogens (Candida, Cryptococcus, Aspergillus); plant fungal and bacterial pathogens (Fusarium and Streptomyces); biological control
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

This special issue will focus on the development of antifungal agents against human and/or plant fungal pathogens. For human fungal pathogens, approximately 1.2 billion individuals worldwide suffer from fungal infections, and the occurrence of these infections has significantly increased in recent years due to a rise in the number of immunocompromised patients, such as patients with AIDS or those with cancer, organ transplant, or autoimmune disease who require immunosuppressive therapy. Unlike superficial infections that cause local, benign, or self-limiting diseases, invasive fungal infections (IFIs) are deep-seated and include bloodstream and systemic infections as well as infection of specific organs. IFIs are frequently caused by yeast pathogens such as Candida and Cryptococcus; filamentous fungi such as Aspergillus, Fusarium, or Mucor; or less frequently dimorphic fungi, including Coccidioides, Blastomyces, or Histoplasma. Currently, only 3 main classes of antifungals are approved for treatment of patients with IFIs: polyenes, triazoles, and echinocandins. Because our current antifungal therapies have only modest efficacy with significant toxicities, newer antifungal agents or formulations will be urgently needed. Plant fungal pathogens including species in the genus of Fusarium, Magnaporthe, Botrytis, Puccinia, Collectotrichum, Ustilago, and Rhizoctonia can cause enormous losses in yield and quality of many crops, and there are relatively more antifungal choices with >10 classes based on fungicide resistance action committee. However, it is still not sufficient to conquer numerous plant fungal diseases. In summary, this Special Issue plans to highlight the latest research on the development of antifungal agents against human and/or plant fungal pathogens.

Prof. Ying-Lien Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antifungal drug development
  • human fungal pathogens
  • plant fungal pathogens
  • Candida
  • Cryptococcus
  • Aspergillus
  • Fusarium

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop